TII
14.12.2020 10:21:12 CET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced the formation of a board of advisors at Cryptography Research Centre (CRC). The new board of advisors comprises global experts in the field of cryptography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005303/en/
The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.
CRC is one of the initial seven dedicated centres at TII and it is also one of the few global centres bringing together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes in cryptography. Spanning fields from post quantum cryptography (PQC), lightweight cryptography, cryptanalysis, cryptographic protocols, hardware-based cryptography, confidential computing, amongst others, the distinguished board of advisors will guide efforts to develop breakthrough technologies for global impact, reinforcing the UAE’s position as a global hub for innovation and R&D.
The Board of Advisors includes: Prof Joan Daemen , Professor of Symmetric Cryptography at Radboud University in The Netherlands, who co-designed the Rijndael cipher that was selected as the Advanced Encryption Standard (AES) and is also one of the co-designers of the Keccak (SHA-3) cryptographic algorithm; Prof Lejla Batina , Professor of Hardware Cryptography at Radboud University, whose expertise is in applied cryptography and embedded systems security; Dr Guido Bertoni , CEO of Security Pattern, Italy, whose research areas include cryptographic algorithms, hardware-based cryptography, applied cryptography and embedded systems security. He is also a co-designer of the Keccak (SHA-3) cryptographic algorithm. Prof. Carlos Aguilar , Professor of ISAE SUPAERO in Toulouse University, France, a post quantum cryptographer and expert in secure cryptographic implementations and computational theory; Prof. Damien Stehlé , Professor in Computer Science at École Normale Supérieure de Lyon, France, whose focus areas are post quantum cryptography, computational theory and complex algebra; and Prof. Tim Güneysu, Professor of Security Engineering at Ruhr-University Bochum, Germany, who is an expert in secure hardware implementations, cloud cryptographic schemes and secure engineering.
CRC currently employs and collaborates with scientists in multiple crucial fields of cryptography. The experts are engaged in the full spectrum of fundamental and applied cryptography and cryptanalysis research.
Speaking on the board appointments, Dr Najwa Aaraj, Chief Researcher at CRC, said: “The success of any scientific and research-focused entity is led by its board of advisors as they support in setting the vision. By bringing together renowned experts, we are connecting global expertise in the field of cryptography.”
Dr Aaraj added: “Through the research undertaken at the Cryptography Research Centre, we are confident that Abu Dhabi and the UAE will pioneer breakthrough technologies that ensure even greater enhancements in high-priority cryptographic areas.”
TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.
To know more about Cryptography Research Centre (CRC):
tii.ae/cryptographytii.ae/cryptography
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005303/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
